The aim of this observational, multicentric study conducted in metastatic NSCLC patients was to assess the prognostic significance of sPD-1, sPD-L1, VEGFA, sCD40L and sCD44 plasma levels at baseline and after two cycles of anti-PD1 therapy nivolumab. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.